Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL

Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.

Trial Details

NCT ID
NCT07493148
Phase
PHASE2
Sponsor
Ou Bai, MD/PHD
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Chidamide
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Vincristine
  • Prednisone
Locations (sample)
  • Changchun, Jilin, China|43.88,125.32278

Key Eligibility Criteria

  • Age ≥ 70 years;
  • No prior treatment for DLBCL;
  • Histopathologically confirmed diagnosis (all of the following conditions must be met simultaneously): ① Diffuse large B-cell lymphoma, not otherwis…
  • At least one 18F-fluorodeoxyglucose (18FDG)-avid lesion on positron emission tomography-computed tomography (PET-CT) according to the 2014 Lugano c…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →